Abstract
Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have